111In-DTPA-D-Phe1 Archives

Tag: 111In-DTPA-D-Phe1

Also known as Octreotide scintigraphy which uses 111In-labelled octreotide which is a somatostatin analogue; it is also known as an Octreoscan, a brand name for 111In-labelled pentetreotide; pentetreotide is a DTPA-conjugated form of octreotide, originally manufactured by Mallinckrodt Nuclear Medicine LLC, which now forms part of Curium. Other synonyms include Octreoscan, Octreotide Scan.

The radiotracer is characterised by a high affinity of bond with the somatostatin receptor 2 (SST2). It penetrates inside the cell by endocytosis, first held by lysosomes and then transferred to the nucleus. It is particularly useful for assessment of neuroendocrine tumours, and the Krenning Score is used to grade these, most commonly for peptide receptor radionuclide therapy (PRRT) planning. See my article on scans – click here

Clinical Trials and Research, Living with Neuroendocrine Cancer, Treatment111In-DTPA-D-Phe1, 177Lu-Edotreotide (Solucin®), 212Pb-AR-RMX, 64Cu-DOTATATE, Advanced neuroendocrine cancer, Carcinoid tumour, Ga68 PET/CT, Ga68-DOTATOC, Generator (radionuclide), Indium 111-pentetreotide, NETSPOT, Neuroendocrine cancer, Octreotide, Octreotide scan, PRRT, Somatostatin receptors (SSTR), SPECT

Detectnet™ (64Cu-DOTATATE) – an expansion of the Somatostatin Receptor PET Imaging for Neuroendocrine Cancer

By Ronny Allan Aug 30, 2018 2 Comments

Edit 21st January 2021. The imaging time window of 64Cu-DOTATATE positron emission tomography/computed tomography (PET/CT) for patients with neuroendocrine neoplasms can be expanded from one hour to three hours post-injection, according to new research published in the January 2021 issue of The Journal of Nuclear Medicine. Read more here Edit 4th September 2020. 64Cu-dotatate now named Detectnet™ is approved for use by US FDA. Majority read revealed Detectnet had over 98% accuracy, 100% sensitivity, and over 96% specificity to confirm or exclude presence of disease. Read more here. Edit 14th July 2020. Expanded Access Program via clinical trial now recruiting -…